Our asbestos lawyers are encouraged by recent news that doctors at Memorial Sloan Kettering Cancer Center have registered positive results from clinical trials that looked at immunotherapies, or immune checkpoint inhibitors, for fighting mesothelioma and small cell lung cancer (SCLC) instead of chemotherapy.
The magazine Cure® published a story this month in which immune checkpoint inhibitors are showing “encouraging results” for patients with aggressive thoracic illnesses that often result in poor outcomes when treated with chemotherapy. The story came out of a presentation that was delivered during this month’s 10th Annual New York Lung Cancer Symposium, an oncologist convention.
Dr. Maria Catherine Pietanza, an oncologist at Memorial Sloan Kettering Cancer Center, delivered these findings at the Symposium.
“The antibodies to CTLA-4, PD-1, and PD-L1 can be safely given to (SCLC) patients,” she reported said during her presentation. “Responses are seen and are durable. There is a benefit in both platinum-sensitive and platinum-refractory SCLC.”
She added that ongoing clinical trials will continue to record how effective immunotherapies are at treating mesothelioma and small cell lung cancer.
If you’re living with mesothelioma or lung cancer from asbestos exposure, the lawyers at The Williams Law Firm, P.C., in New York City are dedicated to helping you find the resources you need, and that might include new and emerging treatments. Contact us today for your free case consultation by calling (855) 955-6376 .